INTRODUCTION
Implantation failure is the major cause negatively influencing the outcome of assisted reproductive technologies (ART), as only two out of every ten embryos successfully implant. 1 The outcome of intra cytoplasmic sperm injection (ICSI) has been shown to be positively associated with the morphological state of the sperm, while early miscarriage rates were negatively associated with nuclear morphology. 2, 3 However, repeated failure of conventional IVF has been suggested to be caused by a paternal effect on early embryo development, a hypothesis confirmed using a shared oocyte donation model. 4 Bartoov et al developed a method of human spermatozoa evaluation performed in real-time at high magnification called "motile sperm organelle morphology examination" (MSOME). 5, 6 MSOME is performed using an inverted 1 Department of Obstetrics & Gynaecology, Faculty of Medicine, Alexandria University, Egypt 2 Agial fertility Center, Alexandria, Egypt microscope equipped with Normarsk interference contrast optics, which enables observation at high magnification (> 6000×) compared to the 200-400× observed by conventional ICSI. 6 This method led to the development of the intra cytoplasmic morphologically selected sperm injection (IMSI) procedure, which is based on sperm normality as defined by MSOME classification and aims to improve conventional ICSI outcomes by focusing on the correlation between abnormalities in sperm morphology observed at high magnification and DNA damage. 7, 8 Various studies have demonstrated that IMSI significantly improves fertilization rates, embryo quality, the rate of development up to the blastocyst stage, the rates of implantation and pregnancy after embryo transfer on day 2 or 3 or in the blastocyst stage and the likelihood of having a normal healthy child; IMSI also appears to significantly decrease miscarriage rates. 2, 5, [8] [9] [10] [11] 13 In fact, prior failures in ICSI cycles constituted an inclusion criterion in several studies employing IMSI. 3, 14 Various studies have demonstrated that IMSI not significantly improves fertilization rates, implantation and pregnancy rates. [15] [16] [17] To better comprehend the value of IMSI, the purpose of this study was to compare laboratory and clinical outcomes of IMSI versus conventional ICSI in couples with severe male factor and repeated ICSI failures.
The aim and objective of the study was to compare the results of IMSI and ICSI among infertile couples with severe male factor and repeated ICSI failure in terms of: The number of embryos, embryo grading fertilization rate, implantation rate and pregnancy rate which will be diagnosed by: Serum B-HCG assay 14 days after embryo transfer and Clinical pregnancy will be confirmed by observing fetal cardiac pulsations 2 weeks after positive pregnancy test by trans-vaginal ultrasonography (TVS).
METHODS

Study setting & design
This was a comparative prospective randomized controlled study was carried out in Agial IVF/ICSI center, Alexandria, Egypt.
Target population
(140) Infertile couples signed an informed written consent to declare their agreement to be enrolled in the study as agreed upon by the ethical committee.
All underwent ICSI and IMSI due to severe male factor and repeated ICSI failure from June 2014 to February 2015. The couples were randomly subdivided equally into two groups: Female partners of all couples included in the study were selected according to these criteria:
Inclusion criteria: Age below 37 years, primary or secondary infertility, having good ovarian reserve (AMH > 1.5, AFC > 5 and basal FSH < 10mIu/L) and all with at least one previous failed ICSI.
Exclusion criteria: endocrine disorders associated other medical conditions (hypertension, diabetes), abnormal uterine factor diagnosed by vaginal sonography, Hysteroscopy, Hysterosalpingography or previous uterine surgery and stage IV endometrioses or previous ovarian surgery.
Male partners of all couples included in the study were selected according to these criteria:
Inclusion criteria: Severe oligospermia sperm concentration < 5 (10 6 per ml) and severe teratospermia normal forms < 4%.
Exclusion criteria: Cases with TESE (testicular epididimal sperm extraction).
The ovarian stimulation
The long down-regulation protocol was used in all patients as (Decapeptyl®, Ferring) a daily subcutaneous dose of 0.1 mg was started on cycle day 21. On the first day of the new cycle, the serum estradiol was measured. Once a serum estradiol concentration was suppressed to ≤ 50 pg/ml, the dose was reduced to 0.05 mg and continued until the day of HCG administration. Ovarian stimulation with recombinant FSH (Gonal F®, Serono) 150 IU as well as urinary human menopausal gonadotropin (u-HMG) (Merional®, IBSA) 75 IU began following pituitary down-regulation. The standard initial dose was at least 225 Iu/day of recombinant FSH (Gonal F®, Serono) to be adjusted according to patient previous history, ovarian reserve, age and response during the course of treatment.
The ovarian response was monitored by serial serum estradiol concentrations and trans-vaginal ultrasound beginning on day 5 of stimulation until the day of HCG administration. Based on these results, the FSH/HMG dose and subsequent monitoring were individualized. Ovarian stimulation was continued until at least three follicles reach a mean diameter of ≥ 20 mm, at which time HCG (Choriomon®, IBSA) 10,000 IU s.c. or i.m. was administered 36 hour before oocyte retrieval.
Following oocyte retrieval, the patients received luteal phase support in the form of natural progesterone vaginally in a dose of 600 mg/day (Prontogest Supp®, Marcyrl) to continue preparing the endometrium.
ICSI and IMSI procedures
After oocyte retrieval, the cumulus and corona radiata were removed mechanically under a stereomicroscope, after exposure to 80 IU/ml hyalouronidase solution for 30 seconds. Conventional ICSI was done to mature (M II) oocytes with the use of a Hoffman contrast Nikon inverted microscope. Motile normal-looking spermatozoa were selected at x200 magnification to be injected into a mature oocyte. In the IMSI technique, a spermatozoa preselection step was performed at x10, 000 magnification with the use of a Nomarski-contrast Nikon inverted microscope equipped with an x1, 000 magnification oil immersion lens associated with a video camera. This optical system required the use of a glassbottomed dish (Willco GWST 0.17 mm; JCD). An elongated polyvinylpyrrolidone (JCD) 2-mL drop was placed in this dish, covered with an adequate volume of sterile mineral oil (Nidoil; Nidacon International) and inseminated with an adequate amount of selected spermatozoa. Motile spermatozoa for further injection into oocytes were selected under high magnification according to the Vanderzwalmen classification, and transferred into the dish used for classic ICSI procedure before being injected. 18 Briefly, the primary objective was to select spermatozoa displaying a normal oval head shape without vacuoles or with fewer than two vacuoles representing < 4% of the head area (grade 1 or 2) as well as absence of both cytoplasmic extrusion and tail defects. If not available, the second-best spermatozoa with the least number of vacuoles and/or other abnormalities (grade 3 or 4) were selected for injection. 18 Injected oocytes were incubated in appropriate embryo culture media at 37 0 C under 6% CO 2 humidified atmosphere and observed every day, followed by transfer of embryos in the appropriate time.
Assessment of fertilization and cleavage
 Oocytes were examined for fertilization 16-18 h after ICSI or IMSI.  Cleavage of the oocytes was assessed on day 2 (48 h) and day 3 (72 h) day 5 (blastocyst) before transfer into the uterus.
The embryos were graded on a scale of 1 to 5.
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The gardener blastocyst grading scale 20 The expansion grade scale ranges from 1 (least expanded) to 6 (completely hatched).
The day of embryo transfer was day 3 in all cases of both groups except 7 cases in IMSI group and 2 cases in ICSI group were day 5.
B-HCG was measured for diagnosis of pregnancy 14 days after embryo transfer and then was measured serially to monitor the rise in its titre. Implantation was noted later by appearance of the gestational sac in the uterus using TVS. Our study demonstrated that, there were no statistical significant differences between the two studied groups regarding demographic data (age, parity) but demonstrated that, there was statistical significant differences regarding the gravidity which in the IMSI group was significantly lower when compared with the ICSI group Table 1 , there were no statistical significant differences between the two studied groups regarding laboratory data (number of ampoules, number of stimulation days, estrogen level at HCG day, progesterone level at HCG day, endometrial thickness, number of oocyte retrieved, number of metaphase 1 oocyte, number of metaphase 2 oocyte, number of germinal vesicles, number of fractured oocytes) Table 2 , there were no statistical significant differences between the two studied groups regarding (number of class A embryos, number of embryo transferred, number of blastocyst transferred) but demonstrated that, there were statistical significant differences regarding (number of cleaved cells and number of class B embryos) Table 3 , there were no statistical significant differences between the two studied groups regarding fertilization rate, implantation rate and chemical or clinical pregnancy Table 4 , 5 and 6.
RESULTS
DISCUSSION
Currently, ICSI is performed after morphological selection of spermatozoa at 200x to 400x magnification. In this magnification range, spermatozoa carrying defects of the head, neck or tail can be detected, but not nuclear vacuoles. Therefore, magnification of 6000x to 12,500x to select spermatozoa, particularly by virtue of permitting a perfect identification of vacuoles, appears to be a better strategy. But our study not agree with Teixeira et al who reported that IMSI was associated with a significant improvement in clinical pregnancy rate (RR 1.29, 95% CI 1.07 to 1.56, 9 RCTs, 2014 women, I2 = 57%, very-low-quality evidence). 22 Bartoov et al reported that pregnancy rate after modified ICSI was significantly higher than that of the routine ICSI procedure (66.0% vs. 30.0%). 5 Berkovitz et al confirmed that the selection and the subsequent injection of spermatozoa with normal nuclear morphology reduced the risk of major fetal malformations. 12 Setti et al reported similar clinical outcomes in couples undergoing either IMSI or ICSI, except that a significantly higher fertilization rate was observed in the former procedure. 23 Knez et al reported that The IMSI group was characterized by a higher number of blastocysts per cycle than the ICSI group (0.80 vs. 0.65) after a prolonged 5-day embryo culture with a tendency toward higher implantation and pregnancy rates per cycle was achieved in the IMSI group compared to the ICSI group (17.1% vs. 6.8%; 25.0% vs. 8.1%, respectively). 24 Kim et al reported that no significant difference in the fertilization rate between IMSI and previous ICSI cycles (67.7% vs. 65.0%). 25 However, the pregnancy and implantation rates with IMSI were significantly higher than those of the ICSI cycles (33.3% vs. 12.5% and 14.6% vs. 5.4%, respectively; p<0.05).
CONCLUSIONS
The use of IMSI was proved to be of no evident role in improvement of outcome of pregnancy rate in infertile couples with severe male factor and repeated ICSI failure, as analysed data didn't show any significant difference.
Recommendation
More efforts are needed to be done to find effective procedures to improve pregnancy rate in such cases. Further studies are needed to be conducted on a wider scale and to be applied on larger number of cases.
